CRISPR Therapeutics CRSP Equity Issuance Costs In Accounts Payable Accrued Expenses And Other Long Term Liabilities
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept crsp:EquityIssuanceCostsInAccountsPayableAccruedExpensesAndOtherLongTermLiabilities.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's equity issuance costs in accounts payable accrued expenses and other long term liabilities.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's equity issuance costs in accounts payable accrued expenses and other long term liabilities?
- CRISPR Therapeutics (CRSP) reported equity issuance costs in accounts payable accrued expenses and other long term liabilities of $4.14M in Q1 2026.
- How has CRISPR Therapeutics's equity issuance costs in accounts payable accrued expenses and other long term liabilities changed year-over-year?
- CRISPR Therapeutics's equity issuance costs in accounts payable accrued expenses and other long term liabilities increased by 28.6% year-over-year, from $3.22M to $4.14M.